Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
116 hedge funds and large institutions have $480M invested in Epizyme, Inc in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 21 closing their positions.
831% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $1.49M
5% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 38
8% less funds holding
Funds holding: 126 → 116 (-10)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
39% less capital invested
Capital invested by funds: $789M → $480M (-$309M)
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$11.6M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$9.97M |
| 3 |
Morgan Stanley
New York
|
+$4.16M |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$3.92M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$9.93M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$7.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$6.42M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.15M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.02M |
EPZM Hedge Fund Activity: Q3 2021 in Review
116 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q3 2021, worth a combined $480M — down 39% from $789M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of EPZM and 11 opened new positions — a net loss of 10 holders — while 38 trimmed existing stakes and 36 added.
The largest buyer was Platinum Investment Management, opening a new position worth an estimated $11.6M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $9.93M sold.
- 116 institutional investors held Epizyme, Inc (EPZM) as of Q3 2021, down from 126 in Q2 2021.
- Funds reported $480M of Epizyme, Inc stock for Q3 2021, down 39% quarter-over-quarter.
- 11 funds opened new Epizyme, Inc positions in Q3 2021 and 21 closed out, a net change of -10 holders.
- The largest Epizyme, Inc buyer in Q3 2021 was Platinum Investment Management, an estimated $11.6M added.
- The largest Epizyme, Inc seller in Q3 2021 was Granahan Investment Management, an estimated $9.93M sold.
Based on aggregated 13F filings for Q3 2021.